Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.

TAVR safer than SAVR in terms of bleeding, acute kidney injury, atrial fibrillation

26 Apr 2018
In intermediate risk patients, the TAVR is found to have better outcomes

Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.

Pooled analysis of four studies (n=4,355; TAVR: n=2,222) showed that, at 2-year follow-up, TAVR was associated with a significantly lower rate of life-threatening bleeding (risk ratio [RR], 0.45; 95 percent CI, 0.28–0.73; p=0.001), acute kidney injury (RR, 0.48; 0.25–0.93; p=0.03) and new atrial fibrillation (RR, 0.46; 0.33–0.64; p<0.0001).

In contrast, TAVR was inferior to SAVR in terms of permanent pacemaker implantation (RR, 3.01; 1.04–8.72; p=0.04) and aortic-valve reintervention (RR, 3.22; 1.64–6.29; p=0.0006), both of which were significantly more frequent in TAVR patients.

There were no significant differences between the two treatments in terms of deaths (TAVR: 13.7 percent vs SAVR: 15.1 percent; RR, 0.86; 0.67–1.10; p=0.22) and cardiovascular mortality rates (8.87 percent vs 10.08 percent; RR, 0.88; 0.73–1.06; p=0.17). The incidences of stroke (RR, 0.90; 0.73–1.10; p=0.31) and myocardial infarction (RR, 0.99; 0.70–1.39; p=0.93) were also comparable between the interventions.

For the meta-analysis, the databases of PubMed, CENTRAL and EBSCO were searched for randomized controlled trials of patients with severe aortic valve stenosis at low-to-intermediate surgical risk. For inclusion, trials should have compared the safety and clinical outcomes between TAVR and SAVR.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.